Tarsons Products Limited (IN:TARSONS)
:TARSONS
Want to see IN:TARSONS full AI Analyst Report?
TARSONS Stock Chart & Stats
₹230.25
-₹6.55(-1.58%)
At close: 4:00 PM EST
₹230.25
-₹6.55(-1.58%)
Day’s Range― - ―
52-Week Range₹164.15 - ₹405.90
Previous CloseN/A
Volume39.72K
Average Volume (3M)2.32K
Market Cap
₹10.92B
Enterprise Value₹14.82B
Total Cash (Recent Filing)₹313.56M
Total Debt (Recent Filing)₹3.96B
Price to Earnings (P/E)75.9
Beta0.91
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.86%
Share Statistics
EPS (TTM)3.87
Shares Outstanding53,206,280
10 Day Avg. Volume1,556
30 Day Avg. Volume2,322
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)1.51
Price to Sales (P/S)2.27
P/FCF Ratio-134.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)₹4.88B
Bulls Say, Bears Say
Bulls Say
Improving Operating Cash FlowSustained positive operating cash flow into 2026 indicates the core business generates real cash from operations. Over months this supports working-capital needs, funds routine reinvestment without immediate external financing, and provides a foundation to stabilize operations while management addresses profitability and FCF gaps.
Recurring Consumables Business ModelTarsons sells frequently replenished lab consumables and specialized labware, creating repeat demand and customer stickiness from standardized workflows. This structural, recurring revenue mix across domestic and export channels supports predictable volumes and long-term customer relationships versus one-off product cycles.
Supported Balance-sheet ScaleAn expanding asset base and stronger equity provide a capital buffer to fund capacity, absorb shocks, and enable growth initiatives. Over a multi-month horizon this underlying scale improves credit capacity and strategic optionality when paired with stable operating cash generation, assuming leverage is managed.
Bears Say
Rising LeverageSharp debt accumulation since 2023 raises structural risk: higher interest and principal obligations constrain financial flexibility, reduce resilience to demand shocks, and make future investment decisions debt-sensitive. If earnings and margins don't recover, servicing elevated debt will pressure cash flow allocation.
Persistent Negative Free Cash FlowChronic negative free cash flow signals that capital spending and reinvestment exceed internally generated cash. Over months this necessitates external funding or higher leverage, limiting the firm's ability to deleverage, return capital, or absorb setbacks, and may force trade-offs between growth and balance-sheet repair.
Weakened Profitability And MarginsA sustained downtrend in margins and earnings power reduces returns on invested capital and the capacity to self-fund growth. Persistently compressed profitability undermines long-term competitiveness, heightens sensitivity to cost or pricing pressures, and makes it harder to improve leverage or invest in margin-restoring initiatives.
Tarsons Products Limited News
TARSONS FAQ
What was Tarsons Products Limited’s price range in the past 12 months?
Tarsons Products Limited lowest stock price was ₹164.15 and its highest was ₹405.90 in the past 12 months.
What is Tarsons Products Limited’s market cap?
Tarsons Products Limited’s market cap is ₹10.92B.
When is Tarsons Products Limited’s upcoming earnings report date?
Tarsons Products Limited’s upcoming earnings report date is Aug 19, 2026 which is in 66 days.
How were Tarsons Products Limited’s earnings last quarter?
Tarsons Products Limited released its earnings results on May 22, 2026. The company reported ₹0.79 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.79.
Is Tarsons Products Limited overvalued?
According to Wall Street analysts Tarsons Products Limited’s price is currently Overvalued.
Does Tarsons Products Limited pay dividends?
Tarsons Products Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.86%. See more information on Tarsons Products Limited dividends here
What is Tarsons Products Limited’s EPS estimate?
Tarsons Products Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tarsons Products Limited have?
Tarsons Products Limited has 53,206,280 shares outstanding.
What happened to Tarsons Products Limited’s price movement after its last earnings report?
Tarsons Products Limited reported an EPS of ₹0.79 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.83%.
Which hedge fund is a major shareholder of Tarsons Products Limited?
Currently, no hedge funds are holding shares in IN:TARSONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tarsons Products Limited
Established in 1983 and headquartered in Kolkata, India, Tarsons Products Limited specializes in the global manufacturing and distribution of plastic laboratory supplies and scientific instruments. The company's diverse product portfolio features disposable plastic labware, centrifuge and cryogenic equipment, liquid handling systems, and safety products. Its comprehensive catalog further encompasses items such as bottles, carboys, measuring cylinders, cell culture products, electrophoresis apparatus, microscopy and microbiology tools, vacuum desiccators, mini coolers, cryo boxes, beakers, test tube racks, pipette tips, petri dishes, centrifuge tubes, cryogenic and storage vials, Pasteur pipettes, and vortex mixers, among many others. These offerings are vital for research and applications across various scientific disciplines including molecular biology, cell culture, genomics, proteomics, and immunology.
Technical Analysis
Krebs Biochemicals & Industries Ltd.
―
Poly Medicure Limited
―
Vimta Labs Limited
―
Zim Laboratories Ltd.
―
Fischer Medical Ventures Ltd
―